Erbitux® (Cetuximab): New standard in the first line therapy of recurrent and/or metastatic head neck tumours

被引：0
|
作者：
不详
机构：
来源：
ONKOLOGIE | 2009年 / 32卷 / 11期
关键词：
PLUS CETUXIMAB;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：691 / 691
页数：1
相关论文
共 50 条
  • [1] New first line data on Erbitux® (Cetuximab) in gastrointestinal tumours
    不详
    CHIRURGISCHE GASTROENTEROLOGIE, 2006, 22 (04): : 292 - 292
  • [2] Erbitux® (cetuximab) reaches the primary endpoint in the phase III study for first line treatment of head-neck tumours
    Nienstedt, Maren
    ONKOLOGIE, 2007, 30 (06): : 338 - 338
  • [3] How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
    Szturz, Petr
    Seiwert, Tanguy Y.
    Vermorken, Jan B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (20) : 2229 - +
  • [4] Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
    Bernier, Jacques
    ONCOLOGY REVIEWS, 2009, 3 (04) : 247 - 256
  • [5] Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy
    Siano, Marco
    Infante, Gabriele
    Resteghini, Carlo
    Cau, Maria Chiara
    Alfieri, Salvatore
    Bergamini, Cristiana
    Granata, Roberta
    Miceli, Rosalba
    Locati, Laura
    Licitra, Lisa
    Bossi, Paolo
    ORAL ONCOLOGY, 2017, 69 : 33 - 37
  • [6] Cetuximab (Erbitux®) in head and neck cancer, in practice
    Mueller, L.
    Tessen, H. -W
    Goehler, T.
    Doerfef, S.
    Bartels, S.
    Goettel, R.
    ONKOLOGIE, 2010, 33 : 129 - 129
  • [7] Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?
    Vitale, Pasquale
    De Falco, Vincenzo
    Addeo, Raffaele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (07) : 481 - 484
  • [8] The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer
    Koukourakis, G.
    Kouloulias, V.
    Koukourakis, M.
    Kouvaris, J.
    Zacharias, G.
    Gouliamos, A.
    JOURNAL OF BUON, 2009, 14 (01): : 19 - 25
  • [9] First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial
    Bossi, P.
    Hollander, L. H.
    Miceli, R.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Merlano, M.
    Caponigro, F.
    Moro, C.
    Vaccher, E.
    Alabisio, O.
    Caldara, A.
    Russo, A.
    Ferrau, F.
    Nole, F.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Efficacy and safety of pembrolizumab in recurrent or metastatic head and neck carcinoma as first-line therapy
    Ito, K.
    Nakanome, A.
    Morita, S.
    Imai, T.
    Asada, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1402 - S1402
12345